3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia

3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia

Respiratory failure due to developmental immaturity of the pulmonary parenchyma remains the single most common reason for admission to the Neonatal Intensive Care Unit (NICU). The clinical continuum spans acute neonatal Respiratory Distress Syndrome (RDS) immediately following delivery to chronic Bronchopulmonary Dysplasia (BPD) weeks or months later. The Pediatric Pharmacy Specialist must possess in-depth mastery of surfactant biophysics, comparative pharmacology of animal-derived surfactant products, modern non-invasive delivery techniques, and evidence-based pharmacotherapy for chronic lung disease.

---

Pathophysiology of Respiratory Distress Syndrome (RDS)

RDS (historically termed hyaline membrane disease) is primarily a disease of developmental surfactant deficiency affecting premature infants. The incidence is inversely proportional to gestational age, occurring in roughly 80% to 90% of infants born at < 28 weeks, 50% to 60% at 29 to 32 weeks, and < 5% at > 34 weeks of gestation.

Surfactant Synthesis & Composition

Pulmonary surfactant is synthesized, stored in intracellular lamellar bodies, and exocytosed into the alveolar hypophase by alveolar type II pneumocytes beginning around 24 to 28 weeks of gestation, with mature alveolar pools typically achieved by 35 to 36 weeks. Structurally, pulmonary surfactant consists of:

• Phospholipids (~80% to 85%): Primarily dipalmitoylphosphatidylcholine (DPPC), also known as disaturated phosphatidylcholine. DPPC contains two saturated palmitic acid chains that pack tightly at the air-liquid interface to generate near-zero surface tension upon alveolar compression.
• Neutral Lipids (~8% to 10%): Chiefly cholesterol, which modulates surfactant film fluidity and spreading dynamics.
• Surfactant-Associated Proteins (~5% to 10%):
  • Hydrophobic Proteins (SP-B and SP-C): Essential for biophysical function. SP-B and SP-C accelerate the rapid insertion, spreading, and re-spreading of phospholipids into the monolayer during dynamic respiratory cycling. Genetic deficiency of SP-B is an autosomal recessive condition causing lethal neonatal respiratory failure curable only by lung transplantation.
  • Hydrophilic Proteins (SP-A and SP-D): Calcium-dependent lectins (collectins) that function within the innate pulmonary immune system, opsonizing bacteria, viruses, and fungi while regulating alveolar inflammation.

Biomechanical Consequences: The Law of Laplace

The physical stability of spherical terminal alveoli is dictated by the Law of Laplace:

$P = \frac{2T}{r}$

Where:

• $P$ = Collapsing pressure required to keep the alveolus open
• $T$ = Surface tension at the alveolar air-liquid interface
• $r$ = Radius of the alveolus

In the absence of surfactant, surface tension ($T$) remains constant and high (~70 dynes/cm, equivalent to pure water). As an infant exhales, alveolar radius ($r$) decreases; according to the equation, the collapsing pressure ($P$) escalates dramatically. Smaller alveoli empty their volume into larger alveoli, precipitating diffuse microatelectasis, decreased functional residual capacity (FRC), intrapulmonary right-to-left shunting, severe ventilation-perfusion ($V/Q$) mismatch, hypoxemia, and mixed respiratory/metabolic acidosis. Alveolar epithelial injury and capillary endothelial leak lead to the exudation of fibrin and plasma proteins into the alveolar spaces, creating the classic "hyaline membranes" on histology.

---

Comparative Pharmacology of Exogenous Surfactant Preparations

Natural animal-derived surfactants are significantly superior to synthetic first-generation surfactants (which lacked surfactant proteins). Three natural surfactant products are currently approved in the United States:

Clinical Evidence & Selection Rationale

Randomized controlled trials and meta-analyses (including Cochrane systematic reviews) demonstrate that an initial poractant alfa dose of 200 mg/kg (yielding 2.5 mL/kg volume) provides significantly faster weaning of supplemental fraction of inspired oxygen ($\text{FiO}_2$) and lower acute mortality before hospital discharge compared to initial 100 mg/kg regimens of beractant or calfactant. Furthermore, the lower instillation volume of poractant alfa (2.5 mL/kg vs 4.0 mL/kg for beractant) markedly reduces the incidence of transient endotracheal tube obstruction, bradycardia, and oxygen desaturation during intratracheal instillation.

Surfactant Handling & Administration Rules

• Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F) protected from light.
• Warming: Bring vial to room temperature for roughly 20 to 30 minutes prior to administration. Never microwave or use artificial heat sources, as heat denatures the hydrophobic SP-B and SP-C tertiary protein structures.
• Mixing: Inspect vial for discoloration or particulate matter. Gently invert the vial several times without shaking. Shaking causes extensive foaming and denatures the surfactant proteins.
• Ventilator Management: Immediately post-instillation, alveolar compliance improves rapidly. Clinicians must actively monitor chest excursion and immediately wean peak inspiratory pressure (PIP) or tidal volume and $\text{FiO}_2$ to prevent pulmonary overdistension, pneumothorax, and pulmonary hemorrhage.

---

Surfactant Delivery Modalities: INSURE vs LISA/MIST

The historic paradigm of universal intubation and mechanical ventilation for surfactant delivery has been superseded by non-invasive delivery modalities designed to eliminate ventilator-induced lung injury (VILI):

                    Surfactant Delivery Paradigms in Spontaneously Breathing Preterm Infants
                    
                         [ Preterm Infant on Non-Invasive CPAP with RDS ]
                                                 |
                     +---------------------------+---------------------------+
                     |                                                       |
             INSURE Technique                                        LISA / MIST Technique
                     |                                                       |
        1. Endotracheal Intubation                              1. Maintain Infant on Non-Invasive CPAP
        2. Surfactant Instillation via ETT                      2. Direct / Video Laryngoscopy
        3. Positive Pressure Ventilation                        3. Thread Thin Vascular Catheter (16-18G)
        4. Extubation to CPAP (< 1 hour)                           Through Vocal Cords into Trachea
                     |                                          4. Instill Surfactant Slowly over 1-3 min
        Drawbacks:                                                 While Infant Breathes Spontaneously
        - Exposure to positive pressure cycles                  5. Immediately Remove Catheter
        - Risk of failed extubation                                          |
        - Laryngeal / tracheal trauma                           Benefits:
                                                                - Zero positive pressure cycles
                                                                - Preserves native laryngeal braking
                                                                - Significant reduction in BPD / Death

1. INSURE (INtubation, SURfactant, Extubation): The infant is intubated, given endotracheal surfactant with positive pressure bagging or mechanical ventilation, and extubated directly to Continuous Positive Airway Pressure (CPAP) within 60 minutes. While superior to prolonged mechanical ventilation, INSURE still exposes immature alveolar sacs to cyclic positive pressure volutrauma.
2. LISA (Less Invasive Surfactant Administration) / MIST (Minimally Invasive Surfactant Therapy): The infant remains on non-invasive CPAP breathing spontaneously. Under direct or video laryngoscopy, a thin, flexible catheter (e.g., 16–18 gauge vascular catheter, Angiocath, or dedicated surfactant catheter) is threaded through the vocal cords into the mid-trachea. Surfactant is instilled over 1 to 3 minutes while the infant's spontaneous breaths distribute the drug into the distal lung via negative inspiratory pressure. Landmark randomized trials (such as the OPTIMIST-A trial) have demonstrated that LISA/MIST significantly reduces the need for mechanical ventilation within the first 72 hours of life and lowers the composite outcome of death or BPD at 36 weeks postmenstrual age.

---

Bronchopulmonary Dysplasia (BPD): Pathogenesis & Modern Classification

BPD represents the chronic, maladaptive pulmonary sequel of prematurity. In the modern era of surfactant replacement and gentle ventilation, classic BPD (severe airway fibrosis and smooth muscle hypertrophy from aggressive ventilation) has been replaced by "New BPD"—characterized by arrest of alveolar and vascular development (fewer, simplified, hyper-enlarged alveoli with a severely decreased surface area for gas exchange and dysmorphic capillary networks).

The Jensen 2021 NICHD BPD Diagnostic Criteria

In 2021, the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network refined the diagnostic definition and severity grading of BPD, evaluated strictly at 36 weeks postmenstrual age (PMA):

• No BPD: Spontaneously breathing on room air without respiratory support at 36 weeks PMA.
• Grade 1 BPD: Requiring low-flow nasal cannula $\le 2\text{ L/min}$ supplemental oxygen.
• Grade 2 BPD: Requiring nasal cannula $> 2\text{ L/min}$ or non-invasive positive airway pressure (NCPAP, NIPPV).
• Grade 3 BPD: Requiring invasive mechanical ventilation via endotracheal tube.

---

Prevention & Pharmacotherapy of BPD

1. Caffeine Citrate Prophylaxis & The CAP Trial

Initiation of caffeine citrate within the first 72 hours of life (and frequently < 24 hours) is standard of care in VLBW neonates (< 1,250 g). The landmark Caffeine for Apnea of Prematurity (CAP) trial enrolled 2,006 VLBW infants, demonstrating that early caffeine therapy:

• Significantly reduced the incidence of BPD (47% in caffeine group vs 63% in placebo group, $p < 0.001$).
• Significantly accelerated weaning from mechanical ventilation and CPAP (mean reduction of 1 to 2 weeks).
• Improved neurodevelopmental outcomes at 18 to 21 months of corrected age, including a significant reduction in cerebral palsy (OR 0.58) and cognitive delay.

2. Postnatal Systemic Corticosteroids: Balancing Efficacy & Neurotoxicity

Inflammation drives alveolar arrest in BPD. However, corticosteroids present a profound clinical trade-off between pulmonary improvement and neurodevelopmental toxicity:

The Danger of Early High-Dose Dexamethasone (< 7 Days of Life):

During the 1990s, neonatologists utilized early high-dose dexamethasone (0.5 mg/kg/day tapering over 4 weeks) starting within the first week of life to prevent BPD. Subsequent long-term randomized follow-up trials revealed a catastrophic increase in cerebral palsy (relative risk 1.7 to 2.0), adverse neuromotor development, gastrointestinal perforation, and stunted somatic/head growth. Consequently, the American Academy of Pediatrics (AAP) strictly contraindicated early routine systemic dexamethasone for BPD prevention.

The DART Low-Dose Dexamethasone Protocol (>= 7 to 14 Days of Life):

For infants who remain ventilator-dependent with evolving severe BPD beyond the first 1 to 2 weeks of life, the Dexamethasone: A Randomized Trial (DART) protocol established a safe, low-dose, 10-day tapering regimen that successfully facilitates extubation without neurodevelopmental harm:

Clinical Outcomes: The DART trial achieved significantly higher extubation rates by day 10 compared to placebo (60% vs 12%, $p < 0.001$) and demonstrated no statistically significant differences in cerebral palsy, death, or major neurodevelopmental disability at 2 years of age.

Alternative Steroids: Hydrocortisone & Inhaled Corticosteroids:

• Hydrocortisone: The multicenter PREMILOC trial evaluated early, physiological-dose hydrocortisone (1 mg/kg/day divided q12h for 7 days, then 0.5 mg/kg/day for 3 days) in infants born at 24 to 27 weeks gestation. Results showed significantly improved survival without BPD at 36 weeks PMA without neurodevelopmental harm at 2 years of age. However, when hydrocortisone is combined with indomethacin for PDA closure, the risk of spontaneous intestinal perforation (SIP) increases dramatically.
• Inhaled Corticosteroids (Budesonide): Evaluated in the European NEUROSIS trial to target pulmonary inflammation while avoiding systemic toxicity. While inhaled budesonide reduced BPD rates, long-term follow-up noted an unexplained, borderline increase in mortality in the budesonide arm, preventing widespread adoption as universal prophylaxis.

3. Diuretic Pharmacotherapy in Established BPD

Diuretics are widely employed in the NICU to treat acute pulmonary edema, decrease interstitial lung fluid, and enhance dynamic compliance in infants with evolving BPD. However, chronic therapy carries substantial metabolic hazards:

Loop Diuretics (Furosemide):

• Mechanism: Inhibits the $\text{Na}^+/\text{K}^+/2\text{Cl}^-$ symporter in the thick ascending limb of Henle. Dose: 1 mg/kg IV or 2 mg/kg PO.
• Chronic Complications: Profound urinary calcium wasting causing hypercalciuria, nephrocalcinosis (renal parenchymal and medullary calcium deposition detectable on ultrasound), nephrolithiasis, and osteopenia of prematurity (metabolic bone disease with pathological rib fractures). Additionally causes hypokalemic, hypochloremic metabolic alkalosis and ototoxicity (synergistic with aminoglycosides).

Thiazide & Potassium-Sparing Diuretics (Chlorothiazide + Spironolactone):

• Mechanism: Chlorothiazide (10–20 mg/kg/dose PO q12h) inhibits the $\text{Na}^+/\text{Cl}^-$ cotransporter in the distal convoluted tubule; spironolactone (1–1.5 mg/kg/dose PO q12h) competitively antagonizes aldosterone in the cortical collecting tubule.
• Renal Advantage: Unlike loop diuretics, thiazides enhance distal tubular calcium reabsorption, sparing renal calcium and mitigating the risk of nephrocalcinosis and bone demineralization. Combination chlorothiazide/spironolactone is preferred for chronic outpatient and subacute inpatient management of pulmonary edema in established BPD, requiring regular monitoring of serum potassium, sodium, and chloride.